All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked, What are the key considerations of the updated guidelines for early relapsed multiple myeloma?
What are the key considerations of the updated guidelines for early relapsed multiple myeloma?
Kumar begins by defining the differences between early and late relapses in multiple myeloma. Kumar then references key considerations from the updated NCCN guidelines for multiple myeloma (https://jnccn.org/view/journals/jnccn/20/1/article-p8.xml), such as the use of 3-drug combinations rather than 2-drug combinations. Kumar also discusses the use of anti-CD38 antibodies, proteasome inhibitors, and immunomodulatory drugs in early relapsed multiple myeloma.
Novel risk score for predicting early relapse in patients with multiple myeloma
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis, as are high-risk cytogenetic features and failure...
A comprehensive guide on when and how to treat early relapsed multiple myeloma
In recent years, the treatment options for relapsed multiple myeloma (MM) have dramatically improved due to the introduction of novel agents and combinations with...
How to treat first relapse in lenalidomide-refractory MM?
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How to treat first relapse in...
Subscribe to get the best content related to multiple myeloma delivered to your inbox